Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

Q4 2023 SAGE Therapeutics Inc Earnings Call Transcript

Feb 14, 2024 / 01:00PM GMT
Release Date Price: €23 (+6.48%)
Operator

Good morning. Welcome to Sage Therapeutics' Fourth Quarter and Full Year 2023 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on the Investors and Media section of Sages' website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the expressed written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Ashley Kaplowitz, Executive Director of Investor Relations and Capital Markets at Sage.

Ashley Kaplowitz
Sage Therapeutics, Inc. - Director of IR

Good morning and thank you for joining Sage Therapeutics' fourth quarter and full year 2023 financial results conference call. Before we begin, I encourage everyone to go to the Investors and Media section of our website at sagerx.com where you can find the press release and slides related to today's call.

I would like to point out that we will be making forward-looking statements which are based on our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot